financetom
Business
financetom
/
Business
/
US FDA approves Roche's drug for a chronic blood disorder
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
US FDA approves Roche's drug for a chronic blood disorder
Jun 21, 2024 12:35 PM

June 21 (Reuters) - The U.S. Food and Drug

Administration has approved Roche's drug for a chronic

blood disorder, according to the regulator's website.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BMO Says Precious Metals Save Canada's Trade Balance
BMO Says Precious Metals Save Canada's Trade Balance
Mar 11, 2026
06:12 AM EST, 01/09/2026 (MT Newswires) -- Canada's trade balance deteriorated mildly to a small deficit of $600 million in October following a small surplus in the previous month, said Bank of Montreal (BMO). Surprisingly, the deterioration wasn't worse, noted the bank after the release on Thursday of international merchandise trade data. Indeed, exports were expected to step back from...
Denmark's Pandora posts lower prelim Q4 sales on weak consumer sentiment
Denmark's Pandora posts lower prelim Q4 sales on weak consumer sentiment
Mar 11, 2026
Overview * Jewellery brand's preliminary Q4 2025 organic growth at4%, EBIT margin around 33.5% * Company faced weak consumer sentiment in North Americaduring Q4 2025 * Pandora to announce full-year results and ‌strategicpriorities on February 5, 2026Outlook * Pandora expects 2025 organic growth of ​6%, below priorguidance of 7-8% * Pandora anticipates 2025 EBIT ‍margin to be around 24% *...
Jewellery maker Pandora says weak consumer sentiment hits growth
Jewellery maker Pandora says weak consumer sentiment hits growth
Mar 11, 2026
STOCKHOLM, Jan 9 (Reuters) - Danish jewellery group Pandora warned on Friday its full-year organic sales growth for 2025 would ‌land at 6%, below its previous ​guidance of 7-8%, sending its ‍shares down. Pandora said in ⁠a preliminary ⁠reading of 2025 results that it ‌expected an operating ​profit margin of around 24%, in line with ⁠its previous guidance. The ‍top-line ​performance...
Haemonetics Acquires Vivasure Medical Limited
Haemonetics Acquires Vivasure Medical Limited
Mar 11, 2026
BOSTON, Jan. 9, 2026 /PRNewswire/ -- Haemonetics Corporation ( HAE ) , a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced the acquisition of Vivasure Medical Limited (Vivasure), a Galway, Ireland-based company pioneering next-generation technology for percutaneous vessel closure. Vivasure's PerQseal® Elite system uses a proprietary bioabsorbable patch to seal large-bore (up...
Copyright 2023-2026 - www.financetom.com All Rights Reserved